# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Name change to "Talphera" reflects a new era of the Company in partnership with the medical community developing novel ...
Use of CRRT increased during COVID and remained at these higher utilization levelsStudy results demonstrate challenges physicia...
Shares of Green Giant Inc. (NASDAQ: GGE) fell sharply in pre-market trading after announcing a proposed public offering. Gre...
HC Wainwright & Co. analyst Ed Arce reiterates AcelRx Pharmaceuticals (NASDAQ:ACRX) with a Buy and maintains $5 price ta...
AcelRx Pharmaceuticals (NASDAQ:ACRX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate o...